Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia
Lipocalin 2 (LCN2) has been recently identified as an endogenous regulator of appetite. Here, using pancreatic cancer as a model of cachexia, the authors demonstrate that LCN2 is a critical mediator of cancer-associated anorexia and may be therapeutically targeted to improve patient outcomes.
Main Authors: | Brennan Olson, Xinxia Zhu, Mason A. Norgard, Peter R. Levasseur, John T. Butler, Abigail Buenafe, Kevin G. Burfeind, Katherine A. Michaelis, Katherine R. Pelz, Heike Mendez, Jared Edwards, Stephanie M. Krasnow, Aaron J. Grossberg, Daniel L. Marks |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-22361-3 |
Similar Items
-
MyD88 signalling is critical in the development of pancreatic cancer cachexia
by: Xinxia Zhu, et al.
Published: (2019-04-01) -
Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer
by: Kevin G Burfeind, et al.
Published: (2020-05-01) -
Neural Mechanisms of Cancer Cachexia
by: Brennan Olson, et al.
Published: (2021-08-01) -
Gut hormones, appetite suppression and cachexia in patients with pulmonary TB.
by: Suzanne W Chang, et al.
Published: (2013-01-01) -
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
by: Katherine A. Michaelis, et al.
Published: (2019-10-01)